Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/8677Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tentolouris, N. | en |
| dc.contributor.author | Boutati, E. | en |
| dc.contributor.author | Karambakalis, N. | en |
| dc.contributor.author | Perea, D. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Tsoukala, C. | en |
| dc.contributor.author | Kyriaki, D. | en |
| dc.contributor.author | Lourida, E. | en |
| dc.contributor.author | Anastasopoulou, I. | en |
| dc.contributor.author | Karafoullidou, A. | en |
| dc.contributor.author | Raptis, S. A. | en |
| dc.contributor.author | Katsilambros, N. | en |
| dc.date.accessioned | 2015-11-24T16:43:17Z | - |
| dc.date.available | 2015-11-24T16:43:17Z | - |
| dc.identifier.issn | 0939-4753 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/8677 | - |
| dc.rights | Default Licence | - |
| dc.subject | type 2 diabetes | en |
| dc.subject | postprandial | en |
| dc.subject | coagulation | en |
| dc.subject | fibrinolysis | en |
| dc.subject | lipaemia | en |
| dc.subject | hyperglycaemia | en |
| dc.subject | lipoprotein subfractions | en |
| dc.subject | nateglinide | en |
| dc.subject | follow-up | en |
| dc.subject | mellitus | en |
| dc.subject | lipoproteins | en |
| dc.subject | activation | en |
| dc.subject | mortality | en |
| dc.subject | insulin | en |
| dc.subject | niddm | en |
| dc.subject | atherosclerosis | en |
| dc.subject | glibenclamide | en |
| dc.subject | population | en |
| dc.title | Acute nateglinide administration in subjects with type 2 diabetes: Effects on postprandial metabolism, coagulation, and fibrinolysis | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | DOI 10.1016/j.numecd.2004.06.002 | - |
| heal.identifier.secondary | <Go to ISI>://000228903000003 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0939475304000031/1-s2.0-S0939475304000031-main.pdf?_tid=7312fb7e8b602c6a5ade404c3bf67034&acdnat=1333111854_a2932f4ff9c04e04ec340f4ac58c9818 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2005 | - |
| heal.abstract | Background and aim: Postprandial glycaemia and lipaemia are known risk factors for atherosclerosis in type 2 diabetes. Coagulation activation in the postprandial. state also contributes to acceleration of atherosclerosis. Nateglinide is effective in reducing postprandial glycaemia. Its effect on glycaemia may also be beneficial in postprandial lipaemia and coagulation. The aim of this study was to examine the potential effect of a single dose of nateglinide on postprandial triglyceridaemia, coagulation, and fibrinolysis in patients with type 2 diabetes. Methods and results: Ten subjects with type 2 diabetes, treated with diet alone were recruited in a crossover randomized study. In the morning, after a 12- to 14-h fast, each subject received a standard mixed meat (total energy 783 kcal), preceded by one tablet of 120 mg nateglinide or placebo. Venous blood samples were drawn prior to meat consumption and 6 h afterwards for the measurement of plasma glucose, insulin, and C-peptide, lipids, coagulation, and fibrinolysis factors. As expected, there was a significant reduction in postprandial glycaemia after nateglinide administration compared to placebo (P < 0.001). Plasma insulin levels were significantly higher after nateglinide than after placebo (P = 0.002). Nateglinide administration resulted in a lower overall postprandial reduction of tissue-plasminogen activator than placebo (-2.9 &PLUSMN; 1.3 vs. -8.3 &PLUSMN; 3.7 ng/ml h, P = 0.003). In addition, a significant reduction of postprandial plasminogen activator inhibitor-1 was observed in comparison with the baseline values after nateglinide (P = 0.001), although the overall response was not significantly different after nateglinide and placebo (P = 0.31). Plasma concentrations of C-peptide, lipids and the remaining coagulation parameters studied were not different between nateglinide and placebo. Conclusions: Acute nateglinide administration improves postprandial glycaemia and fibrinolytic activity in patients with type 2 diabetes. This combined effect, if confirmed by a long-treatment study, might reduce cardiovascular risk in type 2 diabetes. © 2005 Published by Elsevier Ltd. | en |
| heal.publisher | Elsevier | en |
| heal.journalName | Nutrition Metabolism and Cardiovascular Diseases | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Tentolouris-2005-Acute nateglinide ad.pdf | 123.7 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
